Study the immunomodulatory effect of hydroxychloroquine in recurrent pregnancy loss patients in their current pregnancy

Mamta Singh

doi:10.18203/2320-1770.ijrcog20243155

Authors

Mamta Singh Department of Obstetrics and Gynecology, Sparsh Hospital, Kannauj, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20243155

Keywords:

HCQS, Recurrent pregnancy loss, Immunomodulatory effect

Abstract

Background: Recurrent pregnancy loss is defined as 3 or more pregnancy loss consecutively. in most of the cases cause of pregnancy loss remains unclear. lethal chromosomal abnormality is commonly found in product of conception. HCQ has an impact on innate immunity by decreasing the circulatory level of interleukin-1, TNF-alpha and interferon-gamma. In this way this creates a normal environment that favour normal pregnancy development. This study was aimed to find out the effect of HCQ in RPL patients who have raised TNF alpha and anti-nuclear antibody.

Methods: This is a clinical interventional cross over design study. All patients included in the study were given 200 mg HCQ twice a day with ecosprin 75 mg HS and folic acid 5 mg. After first trimester iron and calcium are also included in the treatment along with previous treatment. HCQ is continued till delivery.

Results: The result of this study shows that there is a significant decrease in the serum value of TNF alpha and after treatment with HCQ in three months. The p value is less than 0.001 for TNF alpha and 0.001 for ANA. This shows that HCQ treatment in recurrent miscarriage patients decreases the serum value of TNF and ANA to a significant level and helps in continuation of pregnancy.

Conclusion: It can be concluded that the use of HCQ showed a decrease in TNF alpha and antinuclear antibody in an ongoing pregnancy, which diminished the chances of recurrent pregnancy loss.

Metrics

Metrics Loading ...

References

Branch DW, Gibson M, Silver RM. Clinical practice. Recurrent miscarriage. N Engl J Med. 2010;363(18):1740-7.

Ogasawara M, Aoki K, Okada S, Suzumori K. Embryonic karyotype of abortuses in relation to the number of previous miscarriages. Fertil Steril. 2000;73(2):300-4.

Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med. 2003;9(3):331-7.

Li W, Zheng X, Gu JM, Ferrell GL, Brady M, Esmon NL, et al. Extraembryonic expression of EPCR is essential for embryonic viability. Blood. 2005;106(8):2716-22.

Laude I, Rongières-Bertrand C, Boyer-Neumann C, Wolf M, Mairovitz V, Hugel B, et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost. 2001;85(1):18-21.

Rai R, Tuddenham E, Backos M, Jivraj S, El'Gaddal S, Choy S, et al. Thromboelastography, whole-blood haemostasis and recurrent miscarriage. Hum Reprod. 2003;18(12):2540-3.

de Saint Martin L, Duchemin J, Bohec C, Couturaud F, Mottier D, Collet M, et al. Increased thrombin generation measured in the presence of thrombomodulin in women with early pregnancy loss. Fertil Steril. 2011;95(5):1813-5.

Pasquier E, De Saint Martin L, Bohec C, Collet M, George FD, Mottier D. Unexplained pregnancy loss: a marker of basal endothelial dysfunction? Fertil Steril. 2013;100(4):1013-7.

Kharazmi E, Dossus L, Rohrmann S, Kaaks R. Pregnancy loss and risk of cardiovascular disease: a prospective population-based cohort study (EPIC-Heidelberg). Heart. 2011;97(1):49-54.

Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyá K, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362(17):1586-96.

Clark P, Walker ID, Langhorne P, Crichton L, Thomson A, Greaves M, et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood. 2010;115(21):4162-7.

Visser J, Ulander VM, Helmerhorst FM, Lampinen K, Morin-Papunen L, Bloemenkamp KWM, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost. 2011;105(2):295-301.

Pasquier E, de Saint Martin L, Bohec C, Chauleur C, Bretelle F, Marhic G, et al. Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial. Blood. 2015;125(14):2200-5.

Kniotek M, Zych M, Roszczyk A, Szafarowska M, Jerzak MM. Decreased production of TNF-α and IL-6 inflammatory cytokines in non-pregnant idiopathic RPL women immunomodulatory effect of sildenafil citrate on the cellular response of idiopathic RPL women. J Clin Med. 2021;10(14):3115.

Lee SK, Na BJ, Kim JY, Hur SE, Lee M, Gilman-Sachs A, et al. Determination of clinical cellular immune markers in women with recurrent pregnancy loss. Am J Reprod Immunol. 2013;70(5):398-411.

Nakashima A, Shima T, Inada K, Ito M, Saito S. The balance of the immune system between T cells and NK cells in miscarriage. Am J Reprod Immunol. 2012;67(4):304-10.

Rai R, Regan L. Recurrent miscarriage. Lancet. 2006;368(9535):601-11.

Figueiredo AS, Schumacher A. The T helper type 17/regulatory T cell paradigm in pregnancy. Immunology. 2016;148(1):13-21.

Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev. 2006;2:CD000112.

Egerup P, Lindschou J, Gluud C, Christiansen OB, ImmuReM IPD Study Group. The effects of intravenous immunoglobulins in women with recurrent miscarriages: a systematic review of randomised trials with meta-analyses and trial sequential analyses including individual patient data. PLoS One. 2015;10(10):141588.

Tang AW, Alfirevic Z, Turner MA, Drury JA, Small R, Quenby S, et al. A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant. Hum Reprod. 2013;28(7):1743-52.

Bygbjerg IC, Svenson M, Theander TG, Bendtzen K. Effect of antimalarial drugs on stimulation and interleukin 2 production of human lymphocytes. Int J Immunopharmacol. 1987;9(4):513-9.

van den Borne BE, Dijkmans BA, de Rooij HH, Cessie SL, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol. 1997;24(1):55-60.

Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol. 2000;165(31):1534-40.

Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol. 2013;40(1):30-3.

Raschi E, Borghi MO, Grossi C, Broggini V, Pierangeli S, Meroni PL. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus. 2008;17(10):938-43.

Döring Y, Hurst J, Lorenz M, Prinz N, Clemens N, Drechsler MD, et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology. 2010;215(3):230-41.

Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol. 2005;174(1):485-90.

Mekinian A, Lazzaroni MG, Kuzenko A, Alijotas-Reig J, Ruffatti A, Levy P, et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a european multicenter retrospective study. Autoimmun Rev. 2015;14(6):498-502.

Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study

Pasquier E, Saint-Martin LD, Marhic G, Chauleur C, Bohec C, Bretelle F, et al. Role of hydroxychloroquine in preconception period of recurrent miscarriage patients. Int J Reproduct Concept Gynacol. 2023;12(4):864-7.

Chakrabarti K, McCune WJ. Advances in the clinical use of hydroxychloroquine levels. Curr Opin Rheumatol. 2022;34(3):151-7.

Huybrechts KF, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol. 2021;224(3):1-22.

Dernoncourt A, Hedhli K, Abisror N, Cheloufi M, Cohen J, Kolanska K, et al. Hydroxychloroquine in recurrent pregnancy loss: data from a French prospective multicenter registry. Human Reproduct. 2024;39(9):1934-41.

Moreuil CD, Alavi Z, Elisabeth Pasquier E. Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. Br J Clin Pharmacol. 2020;86(1):39-49.